Aristo Pharma Nordic ApS: Financial statements 2019
CVR: 32328768
Source: annual report 2019, Danish Business Authority
01/01/2019 – 31/12/2019
Aristo Pharma Nordic ApS (CVR 32328768) has filed annual accounts for 2019. In 2019, the company reported a gross profit of EUR 469,744 and a net result of EUR -286,054 compared with EUR -1,875,856 the year before. Equity in the 2019 report amounted to EUR -1,335,903. The company had 6 employees in the financial year.
- Gross Profit
- EUR 469,744
- Profit/Loss
- EUR -286,054
- Equity
- EUR -1,335,903
- Total Assets
- EUR 760,393
- Employees
- 6
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2019 | - | 470K EUR | -286K EUR | -1.3M EUR | 6 |
| 2018 | - | -949K EUR | -1.9M EUR | -3M EUR | 8 |
| 2017 | - | -3.9M EUR | -5M EUR | -1.2M EUR | 10 |
| 2016 | - | -475K EUR | -2.1M EUR | -4.7M EUR | 12 |
| 2015 | - | 145K EUR | -1.6M EUR | -2.7M EUR | 11 |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2019
As of December 5, 2019, Christian Jaaks has joined the board of directors of Aristo Pharma Nordic ApS.
As of December 5, 2019, Anton Alwin Karremann has left the board of directors of Aristo Pharma Nordic ApS.
Aristo Pharma Nordic ApS has published its annual report for 2018. Gross profit came to DKK -948,611, and the net result was DKK -1,875,856.
About Aristo Pharma Nordic ApS
Aristo Pharma Nordic ApS is a Danish company of the type Anpartsselskab based in Skovlunde, founded in 2011. The company is registered under the industry Engroshandel med læge- og hospitalsartikler. The company was previously named AMNEAL NORDIC ApS and COPHARMA ApS. The management consists of John Hudson Kriwet. The board consists of John Hudson Kriwet (chair), Jannes Paul Beeskow and Robert Maciej Szymanski. The company is owned by Aristo Pharma GmbH. The company has 1 employee (2026). In 2025, the company reported revenue of EUR 453,392 and a net result of EUR 21,589 compared with EUR 25,190 the year before. Equity in the 2025 report amounted to EUR 184,874.